ReviewClinical rheumatology2025
Concurrency of systemic sclerosis and sarcoidosis: a case-based review.
Review in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Convergence of Fibrosis and Granulomatous Inflammation: A Case Series on the Diagnostic and Therapeutic Challenges of Systemic Sclerosis and Sarcoidosis Overlap Syndrome.Diagnostics (Basel, Switzerland) · 2026Article
- Coexistence of sarcoidosis and systemic sclerosis with nailfold videocapillaroscopy documentation.Respiratory medicine case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) and sarcoidosis are two rare, multisystem autoimmune diseases with distinct pathophysiologic mechanisms and clinical features. Their coexistence is uncommon and remains an ongoing research subject to determine its significance and underlying mechanisms. Herein, we report the case of a 58-year-old woman with Raynaud's phenomenon, sclerodactyly, and anti-Scl-70 positive, who was initially diagnosed with SSc. Twelve months into treatment, she developed weight loss, fatigue, and progressive respiratory impairment. Imaging revealed mediastinal and mesenteric lymphadenopathy along with fibroatelectatic lung changes. Endobronchial ultrasound-guided biopsy and PET-CT scan suggested sarcoidosis, which was histologically confirmed by the presence of noncaseating granulomas and multinucleated giant cells. The patient was diagnosed with an overlap syndrome of SSc and sarcoidosis and treated accordingly. Clinical improvement and radiologic regression of lymphadenopathy were observed 2 months post-treatment. This is one of the few published cases of concurrent SSc and scleroderma. A review was also performed on the known cases, emphasizing possible pathophysiologic mechanisms, clinical and laboratory findings that can contribute to an early and accurate diagnosis. According to the known evidence, 68.9% of reported cases involve female patients, and in approximately half of them, SSc was diagnosed first. In particular, limited SSc appears to be nearly twice as prevalent as the diffuse form. Our literature review underscores the rarity of this overlap and highlights recurring patterns that may aid in clinical recognition. However, the limited number of reported cases highlights the need for further studies to better define the epidemiology, pathogenesis, and optimal management of this uncommon association.
Indexed as
Identifiers
41108352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.